Recent studies have shown that adipocytes directly negatively regulate hematopoietic stem cell (HSC) function. It has also been shown that visceral adiposity correlates with bone marrow fat content and therefore increased adipocyte-HSC interaction, which may link high body mass index (BMI) with increased negative regulation of HSC function. Clinically, this has significant implications for stem cell transplant patients, particularly as Americans in general and the pediatric population in particular becomes more obese.
Many studies investigating the relationship between BMI and transplant mortality have been done; the results of these studies are somewhat contradictory. Additionally, interpretation of these stud-ies is complicated by the fact that transplant outcome is an endpoint significantly downstream of HSC function, and is influenced by many other factors affected by obesity. We sought to address directly the issue of HSC function as influenced by adiposity, using the clinical endpoint of engraftment as a proxy measure for hematopoietic stem and progenitor cell (HSPC) function.
We performed an analysis of BMI and time to engraftment (TTE) in all patients transplanted at our institution over a two-year interval. We analyzed data separately from allogeneic bone marrow recipients and autologous peripheral blood stem cell recipients. Only data from the first transplant was analyzed when a subject had multiple HSCTs performed. Linear regression was used to evaluate the relationship between BMI and TTE. Sixty-one patients had an allogeneic bone marrow transplant (29 MRD and 32 MURD) and 33 patients had an autologous HSCT during the study period. There was an inverse correlation between BMI and TTE in the allogeneic group (r 5 -0.2971, p 5 0.02). BMI did not correlate with TTE in the autologous HSCT group. BMI also did not correlate with overall survival in either the autologous or the allogeneic group. Importantly, graft cell dose did not correlate with TTE in either population.
The negative correlation between BMI and time to engraftment was unexpected and may be the result of proliferative effects of adipocytes on more mature hematopoietic progenitors. To assess this possibility in a more controlled setting, we have undertaken an analysis of HSC and MPP frequency and function by performing myeloablative transplants in a murine diet-induced obesity (DIO) model. HSCT/BMT has been limited in part due the toxic conditioning regimens, such as irradiation and chemotherapy, deemed necessary for HSC engraftment. We have previously shown that one important barrier to HSC engraftment is availability of HSC niche space. In the absence of pre-transplant conditioning, 99% of HSC niches are occupied with host HSCs and donor HSC engraftment under these conditions is minimal. We have shown in mouse models, that elimination of host mouse HSCs using anti-mouse-ckit monoclonal antibody ACK2 allows for 90% donor HSC engraftment with minimal toxicity in immunodeficient animals, which is sufficient to cure most hematolymphoid disorders.
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We examined the effects of SCF-signaling in human HSCs using various monoclonal antibodies and verified that anti-human-ckit monoclonal antibody SR-1 uniquely inhibits SCF binding. We cultured purified human BM HSC and CB HSC (CD341CD38-CD901CD45RA-Lin-) with SR-1 or 4F7 (a non-active anti-human-ckit clone) and show that SR-1 uniquely inhibits human HSC proliferation in vitro. Interestingly, SR-1 did not induce human HSC cell death via apoptosis, but rather shifted the differentiation profile and increased Glycophorin A1 and CD411 cells (RBC and platelets respectively), and decreased output of CD14, CD13, and CD33 cells (macrophages/myeloid cells).
To examine the depleting capability of SR-1 in vivo, robust human-mouse hematopoietic chimeras were generated using newborn NOD/SCID/IL-2Rg null mice IV transplanted with 1000 human CB HSC post 100cGy. By BM aspirate, average pre-treatment baseline total human bone marrow engraftment (%hCD45) was 58.6%, and myeloid chimerism (%hCD13/33) was 25.4%. The mice were then treated IV with 500ug of SR-1 every other day for 1 week. Human total and myeloid engraftment 8 weeks post treatment decreased by 92.4% and 96.9% respectively, most likely due to depletion of human HSCs that maintain these populations. The remaining persistent human cells in these animals were primarily Oral Presentations S187
